



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 March 2025
EMA/MB/45410/2025 - Adopted
Management Board

Agenda for the 127TH meeting of the Management Board

Held on 13 March 2025, Virtual (09:00 – 14:00)

Chair: Lorraine Nolan

Item	Title	MB action
1.	Draft agenda	For adoption, EMA/MB/45410/2025*
2.	Declarations of competing interests related to the current agenda	Oral report
3.	Minutes from the 126th meeting, held on 11-12 December 2024, adopted by written procedure	For information*, EMA/MB/580677/2024
4.	Election of the Chair of the Management Board (<i>in camera</i>)	By virtual ballot
A	Points for automatic adoption/endorsement/agreement	
A.1	Emergency Task Force (ETF) <ul style="list-style-type: none">Revised Rules of Procedure of Emergency Task Force (ETF)Revised composition of the ETF for preparedness	For information, EMA/MB/54675/2025; For agreement, EMA/36439/2025*; For adoption, EMA/35247/2025*
B	Points for discussion	
B.1	Highlights of the Executive Director	Oral report
B.2	Report from the European Commission	Oral report
B.3	European Medicines Agencies Network Strategy to 2028	For information, EMA/MB/76785/2025; For adoption*, EMA/376542/2024
B.4	EMA Annual Report 2024	For information, EMA/MB/67605/2025; For adoption, EMA/38990/2025*



Item	Title	MB action
B.5	Audit - Revised Global Internal Audit Standards: <ul style="list-style-type: none"> Updated Internal Audit Charter Updated Management Board's decision establishing the Management Board Audits and Risks Group (MBARG) 	For information, EMA/MB/66687/2025; For adoption, EMA/209787/2017, EMA/MB/105013/2023
B.6	MB Decision of the EMA rules concerning the handling of declared interests of staff members and candidates before recruitment	For information, EMA/MB/59912/2025; For adoption*, EMA/MB/259494/2016
B.7	2024 EMA Annual Report on Independence	For information, EMA/MB/65819/2025; For endorsement*, EMA/573980/2024
B.8	2024 EMA Annual Report on the implementation of the EMA's Anti-Fraud Strategy	Oral Report
B.9	African Medicines Agency Governing Board visit to EMA MB June	For information, EMA/MB/48720/2025, EMA/592532/2024
B.10	Update on cybersecurity management at EMA	Oral report
B.11	Clinical Trials in the EU <ul style="list-style-type: none"> Update on CTIS and ACT-EU Demo of CTIS Trial Map 	For information, EMA/MB/64937/2025, EMA/64938/2025
B.12	Network Data Steering Group update	Oral report
C	Points for information only**	
C.1	Outcome of written procedures finalised during the period from 05 December 2024 to 04 March 2025	For information*, EMA/MB/587514/2024
C.2	2024 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission Reporting period: 1 January to 31 December 2024	For information, EMA/MB/48310/2025, EMA/559856/2024*
C.3	Seventeenth six-monthly report on <i>ex ante</i> and retroactive evaluation of projects for the period 1 July to 31 December 2024	For information, EMA/MB/29851/2025, EMA/29852/2025
C.4	Network Portfolio Report	For information, EMA/MB/54018/2025, EMA/54023/2025
C.5	Summary of transfers of appropriations in budget 2024	For information, EMA/MB/63669/2025
C.6	Annual Activity Report (AAR) 2024	For information, EMA/MB/69904/2025, EMA/69085/2025
C.7	ECA Annual report on EU agencies for the financial year 2023	For information

* Documents marked with a star * are intended for publication on the external website.

** Documents in *Additional documents for information* section are not intended for discussion unless specifically requested.